Clinical trials

Overview
Depending on several factors, you may be eligible to participate in clinical trials studying new treatments for paroxysmal nocturnal hemoglobinuria (PNH). Clinical trials are the only way that new treatments… read more

Empaveli (Pegcetacoplan)

Overview
Empaveli is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Empaveli is also known by its drug name, Pegcetacoplan.

…

Fabhalta (Iptacopan)

Overview
Fabhalta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is also known by its drug name, iptacopan.… read more

PiaSky (Crovalimab-Akkz)

Overview
PiaSky is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and children 13 years and older who weigh at least 40 kilograms (around…

Soliris (Eculizumab)

Overview
Soliris is approved by the U.S. Food and Drug Administration (FDA) to treat people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is prescribed for individuals with PNH to reduce hemolysis (destruction…

Ultomiris (Ravulizumab-Cwv)

Overview
Ultomiris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 1 month or older with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is also referred to by its… read more